PR 022

Drug Profile

PR 022

Alternative Names: Hypochlorous acid; PR-022

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Puricore
  • Developer Realm Therapeutics
  • Class Anti-inflammatories; Chlorine compounds; Noncarboxylic acids; Oxides; Reactive oxygen species; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atopic dermatitis

Most Recent Events

  • 23 Oct 2017 Realm Therapeutics plans a phase IIb trial for Atopic dermatitis (In adolescents) (Realm Therapeutics pipeline, October 2017)
  • 23 Oct 2017 Realm Therapeutics plans a pivotal phase III trials for Atopic dermatitis (In children) (Realm Therapeutics pipeline, October 2017)
  • 16 Oct 2017 Realm Therapeutics plans a phase IIa trial for Atopic dermatitis in USA by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top